Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

被引：121

作者：

Rotolo, Antonia ^{[1
]}

Caputo, Valentina S. ^{[1
]}

Holubova, Monika ^{[1
,2
]}

Baxan, Nicoleta ^{[3
]}

Dubois, Olivier ^{[3
]}

Chaudhry, Mohammed Suhail ^{[1
]}

Xiao, Xiaolin ^{[1
]}

Goudevenou, Katerina ^{[1
]}

Pitcher, David S. ^{[1
]}

Petevi, Kyriaki ^{[1
]}

Kachramanoglou, Carolina ^{[4
]}

Iles, Sandra ^{[5
]}

Naresh, Kikkeri ^{[1
]}

Maher, John ^{[6
]}

Karadimitris, Anastasios ^{[1
]}

机构：

[1] Imperial Coll London, Dept Med, Ctr Haematol, London, England

[2] Charles Univ Prague, Med Fac Pilsen, Biomed Ctr, Alej Svobody 76, Plzen 32300, Czech Republic

[3] Imperial Coll London, Dept Med, Biol Imaging Ctr, London, England

[4] Imperial Coll Healthcare NHS Trust, Dept Neuroradiol, London, England

[5] Hammersmith Hosp, Northwest London Pathol, Cellular Pathol, London, England

[6] Kings Coll London, Guys Hosp, Sch Canc & Pharmaceut Sci, London, England

来源：

CANCER CELL | 2018年 / 34卷 / 04期

关键词：

KILLER T-CELLS; INVARIANT NKT CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; VERSUS-HOST-DISEASE; B-CELLS; ADOPTIVE IMMUNOTHERAPY; ALPHA-GLYCOSYLCERAMIDE; DISTINCT SUBSETS; GENE-EXPRESSION; RECEPTOR;

D O I：

10.1016/j.ccell.2018.08.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19(+) B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced anti-lymphoma activity. CAR19-iNKT cells co-operatively activated by CD1d- and CAR19-CD19-dependent interactions are more effective than CAR19-T cells against CD1d-expressing lymphomas in vitro and in vivo. The swifter in vivo anti-lymphoma activity of CAR19-iNKT cells and their enhanced ability to eradicate brain lymphomas underpinned an improved tumor-free and overall survival. CD1D transcriptional de-repression by all-trans retinoic acid results in further enhanced cytotoxicity of CAR19-iNKT cells against CD19(+) chronic lymphocytic leukemia cells. Thus, iNKT cells are a highly efficient platform for CAR-based immunotherapy of lymphomas and possibly other CD1d-expressing cancers.

引用

页码：596 / +

页数：26

共 50 条

[1] Bicistronic CAR Constructs for Dual CD19 and CD20 Targeting
Yang, Shicheng
Lam, Norris
Kochenderfer, James N.
MOLECULAR THERAPY, 2020, 28 (04) : 149 - 150
[2] DUAL-TARGETING CD19 AND NKG2D LIGANDS CAR T-CELLS ARE EFFECTIVE AGAINST CD19 POSITIVE AND CD19 NEGATIVE B CELL MALIGNANCIES
Bolsee, J.
Jacques-Hespel, C.
Violle, B.
Marijsse, J.
Breman, E.
HUMAN GENE THERAPY, 2023, 34 (21-22) : A37 - A38
[3] Beyond CD19 CAR-T cells in lymphoma
Leung, Wingchi K.
Ayanambakkam, Adanma
Heslop, Helen E.
Hill, LaQuisa C.
CURRENT OPINION IN IMMUNOLOGY, 2022, 74 : 46 - 52
[4] Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia
Gardner, Rebecca
Annesley, Colleen
Finney, Olivia
Summers, Corinne
Lamble, Adam J.
Rivers, Julie
Crews, Kaelin
Huang, Lauren
Brown, Christopher
Mgebroff, Stephanie
Lindgren, Catherine
Spratt, Karen
Gustafson, Josh
Johnson, Adam
Park, Julie R.
Jensen, Michael C.
BLOOD, 2018, 132
[5] Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Heard, Amanda
Landmann, Jack H.
Hansen, Ava R.
Papadopolou, Alkmini
Hsu, Yu-Sung
Selli, Mehmet Emrah
Warrington, John M.
Lattin, John
Chang, Jufang
Ha, Helen
Haug-Kroeper, Martina
Doray, Balraj
Gill, Saar
Ruella, Marco
Hayer, Katharina E.
Weitzman, Matthew D.
Green, Abby M.
Fluhrer, Regina
Singh, Nathan
NATURE COMMUNICATIONS, 2022, 13 (01)
[6] CAR-modified T cells targeting CD19—curing the incurable
Lisa Hutchinson
Nature Reviews Clinical Oncology, 2014, 11 (12) : 683 - 683
[7] Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Amanda Heard
Jack H. Landmann
Ava R. Hansen
Alkmini Papadopolou
Yu-Sung Hsu
Mehmet Emrah Selli
John M. Warrington
John Lattin
Jufang Chang
Helen Ha
Martina Haug-Kroeper
Balraj Doray
Saar Gill
Marco Ruella
Katharina E. Hayer
Matthew D. Weitzman
Abby M. Green
Regina Fluhrer
Nathan Singh
Nature Communications, 13
[8] Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
Roddie, Claire
Lekakis, Lazaros J.
Marzolini, Maria A. V.
Ramakrishnan, Aravind
Zhang, Yiyun
Hu, Yanqing
Peddareddigari, Vijay G. R.
Khokhar, Nushmia
Chen, Robert
Basilico, Silvia
Raymond, Meera
Vargas, Frederick Arce
Duffy, Kevin
Brugger, Wolfram
O'Reilly, Maeve A.
Wood, Leigh
Linch, David C.
Peggs, Karl S.
Bachier, Carlos
Budde, Elizabeth Lihua
Batlevi, Connie Lee
Bartlett, Nancy
Irvine, David
Tholouli, Eleni
Osborne, Wendy
Ardeshna, Kirit M.
Pule, Martin A.
BLOOD, 2023, 141 (20) : 2470 - 2482
[9] Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells
Grain, Audrey
Ollier, Jocelyn
Guillaume, Thierry
Chevallier, Patrice
Le Calvez, Baptiste
Eveillard, Marion
Clemenceau, Beatrice
BIOMEDICINES, 2023, 11 (02)
[10] Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo
Zhiqiang Luo
Jiaru Shi
Qiyao Jiang
Guohua Yu
Xiaorui Li
Zhuoying Yu
Jianxun Wang
Yuanyuan Shi
Molecular Biomedicine, 4

← 1 2 3 4 5 →